Engel, Bastian http://orcid.org/0000-0002-0972-3454
Diestelhorst, Jana
Hupa-Breier, Katharina Luise
Kirchner, Theresa
Henjes, Nicole
Loges, Stephanie
Yuksel, Muhammed
Janczyk, Wojciech
Lalanne, Claudine
Zachou, Kalliopi
Oo, Ye H.
Gournay, Jérôme
Pape, Simon
Drenth, Joost P. H.
Renand, Amédée
Dalekos, George N.
Muratori, Luigi
Socha, Piotr
Ma, Yun
Arikan, Cigdem
Baumann, Ulrich
Manns, Michael P.
Wedemeyer, Heiner
Junge, Norman
Jaeckel, Elmar
Taubert, Richard
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (ME3696/3, ME3696/3, KFO250 projects 3, 7, Z1)
Horizon 2020 Framework Programme (RESHAPE)
Else Kröner-Fresenius-Stiftung (KlinStrucMed)
Medizinischen Hochschule Hannover (CORE100 advanced clinician scientist program, Young Faculty Program)
Sir Jules Thorn Charitable Trust
Medizinische Hochschule Hannover (MHH)
Article History
Received: 10 January 2024
Accepted: 26 April 2024
First Online: 8 July 2024
Declarations
:
: RT and EJ are inventors of the patent application for the use of anti-HIP1R for the diagnosis of AIH (European Patent number 18789434.0). Bastian Engel, Jana Diestelhorst, Katharina Luise Hupa-Breier, Theresa Kirchner, Nicole Henjes, Stephanie Loges, Muhammed Yuksel, Wojciech Janczyk, Claudine Lalanne, Kalliopi Zachou, Ye H. Oo, Jérôme Gournay, Simon Pape, Joost PH Drenth, Amédée Renand, George N. Dalekos, Luigi Muratori, Piotr Socha, Yun Ma, Cigdem Arikan, Ulrich Baumann, Michael P. Manns, Heiner Wedemeyer, Norman Junge are nothing to disclose.
: Informed consent was obtained from all individual participants or their parents as applicable included in the study.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (MHH Ethikkommission, Hannover, Germany; approval numbers 1025–2011, 2817–2015 and 2665–2015) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.